Ferre’, L.
Clarelli, F.
Sferruzza, G.
Rocca, M. A.
Mascia, E.
Radaelli, M.
Sangalli, F.
Dalla Costa, G.
Moiola, L.
Aboulwafa, M.
Martinelli Boneschi, F.
Comi, G.
Filippi, M.
Martinelli, V.
Esposito, F.
Funding for this research was provided by:
Fondazione Italiana Sclerosi Multipla (FISM2013/R/13)
Article History
Received: 8 October 2017
Accepted: 7 May 2018
First Online: 13 May 2018
Compliance with ethical standards
:
: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article:L. Ferre’ reports no disclosures.F. Clarelli reports no disclosures.G. Sferruzza reports no disclosures.M.A. Rocca received speaker’s honoraria from Biogen Idec, Novartis, Genzyme, Sanofi-Aventis, Teva, and Merk Serono and receives research support from the Italian Ministry of Health and Fondazione Italiana Sclerosi Multipla.E. Mascia reports no disclosures.M. Radaelli reports no disclosures.F. Sangalli reports no disclosures.G. Dalla Costa reports no disclosures.L. Moiola received honoraria for speaking at meetings or for attending to advisory board from Sanofi-Genzyme, Biogen-Idec, Novartis, and TEVA.M. Aboulwafa reports no disclosures.F. Martinelli Boneschi has received compensation for activities with Teva Neuroscience, Biogen Idec, and Merck Serono as speaker and/or advisor.G. Comi has received compensation for consulting services with the following companies: Novartis, Teva, Sanofi, Genzyme, Merck, Biogen, Excemed, Roche, Almirall, Chugai, Receptos, Forward Pharma and compensation for speaking activities from Novartis, Teva, Sanofi, Genzyme, Merk, Biogen, Excemed, and Roche.M. Filippi is Editor-in-Chief of the Journal of Neurology; serves on a scientific advisory board for Teva Pharmaceutical Industries; has received compensation for consulting services and/or speaking activities from Biogen Idec, ExceMED, Novartis, and Teva Pharmaceutical Industries; and receives research support from Biogen Idec, Teva Pharmaceutical Industries, Novartis, Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla, Cure PSP, Alzheimer’s Drug Discovery Foundation (ADDF), the Jacques and Gloria Gossweiler Foundation (Switzerland), and ARiSLA (Fondazione Italiana di Ricerca per la SLA).V. Martinelli has received honoraria for consulting and speaking activities from Biogen-Idec, Merck, Bayer, TEVA, Novartis, and Genzyme.